This Article Full Text Full Text (PDF) All Versions of this Article: 35/5/1180    most recent 01.STR.0000125011.93188.c6v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chen, T.-Y. Articles by Bhardwaj, A. Search for Related Content PubMed PubMed Citation Articles by Chen, T.-Y. Articles by Bhardwaj, A. Related Collections Animal models of human disease Acute Cerebral Infarction Neuroprotectors

(Stroke. 2004;35:1180.)
© 2004 American Heart Association, Inc.

Original Contributions

Prolonged Opportunity for Ischemic Neuroprotection with Selective -Opioid Receptor Agonist in Rats

Tsung-Ying Chen, MD; Toru Goyagi, MD; Thomas J.K. Toung, MD; Jeffrey R. Kirsch, MD; Patricia D. Hurn, PhD; Raymond C. Koehler, PhD Anish Bhardwaj, MD

From the Departments of Anesthesiology/Critical Care Medicine (T.-Y. C., T.G., T.J.K.T., J.R.K., P.D.H., R.C.K., A.B.) and Neurology (A.B.), Johns Hopkins University School of Medicine, Baltimore, Md; Department of Anesthesiology and Peri-operative Medicine (J.R.K., P.D.H.), Oregon Health and Science University, Portland, Ore.

Correspondence to Dr Anish Bhardwaj, Neuroscience/Critical Care Division, Meyer 8-140, Johns Hopkins Hospital, 600 N Wolfe Street, Baltimore, MD 21287. E-mail abhardwa{at}jhmi.edu

Background and Purpose— We have previously demonstrated that pretreatment with selective -opioid agonist BRL 52537 hydrochloride [(±)-1-(3,4-dichlorophenyl) acetyl-2-(1-pyrrolidinyl) methylpiperidine], provides ischemic neuroprotection following transient focal ischemia in rats. The present study was undertaken to a) define "therapeutic opportunity" for ischemic neuroprotection with BRL 52537, and b) determine if BRL 52537 attenuates ischemia-evoked efflux of dopamine and its metabolites in the striatum in vivo following transient focal ischemia.

Methods— Using the intraluminal filament technique, halothane-anesthetized male Wistar rats were subjected to 2 hours of middle cerebral artery occlusion (MCAO). In a blinded, randomized fashion, rats were treated with saline (vehicle) or 1 mg/Kg/hr BRL 52537 infusion for 22 hours, initiated at onset, 2, 4, or 6 hours of reperfusion (Rep). In a separate set of experiments utilizing in vivo microdialysis, extracellular levels of dopamine and its metabolites were determined in the striatum during 2 hours of MCAO and 3 hours of reperfusion.

Results— Infarct volume (% of contralateral structure; mean ±SEM) in cortex was significantly attenuated when BRL 52537 was administered at reperfusion (22±6%), 2 hours (21±6%), and 4 hours (18±5%) compared with controls (39±5%). In striatum, infarct volume was significantly attenuated when BRL 52537 was administered at reperfusion (38±9%), 2 hours (40±8%), 4 hours (50±8%), and 6 hours (46±9%) as compared with controls (70±4%). A 6- to 8-fold increase in dopamine in microdialysates occurred within 40 minutes of MCAO. Pretreatment with BRL 52537 did not alter microdialysate levels of dopamine or its metabolites in the striatum during MCAO and early reperfusion, as compared with saline controls.

Conclusions— These data demonstrate that BRL 52537 provides robust ischemic neurprotection with a long therapeutic opportunity (at least 6 hours) without altering ischemia-evoked efflux of dopamine (DA) and its metabolites in striatum during ischemia and early reperfusion.

Key Words: infarct • ischemia • kappa(1) opioid receptors • neuroprotection • reperfusion

This article has been cited by other articles:

				S. Husain, D. E. Potter, and C. E. Crosson Opioid Receptor-Activation: Retina Protected from Ischemic Injury Invest. Ophthalmol. Vis. Sci., August 1, 2009; 50(8): 3853 - 3859. [Abstract] [Full Text] [PDF]

				C.-H. Chen, T. J.K. Toung, P. D. Hurn, R. C. Koehler, and A. Bhardwaj Ischemic Neuroprotection With Selective {kappa}-Opioid Receptor Agonist Is Gender Specific Stroke, July 1, 2005; 36(7): 1557 - 1561. [Abstract] [Full Text] [PDF]

				H.-J. Machulla and A. Heinz Radioligands for Brain Imaging of the {kappa}-Opioid System J. Nucl. Med., March 1, 2005; 46(3): 386 - 387. [Full Text] [PDF]